korrents

On the map

Tap a claim on the ring to put it at the centre.

← There are few clear-cut cases in biopharma today where buying an AI system is obviously worth it.

8 connected korrents · 8 moments on record from 25 May 2023 to 10 Jun 2026.

Same subjectSame subjectSame subjectSame subjectSame subjectSame subjectSame subjectSame subject Read this korrent: There are few clear-cut cases in biopharma today where buying an AI system is obviously worth it. There are few clear-cut cases inbiopharma today where buying an AIsystem is obviously worth it. DL Derek Lowe — holds since 2024-10-14 — tap for who they are Same subject: A compound's AI origin story is not by itself a reason to expect it to do better in the clinic. — tap to centre the map on it A compound's AI origin storyis not by itself a reason toexpect it to do better in theclinic. DL Derek Lowe — holds since 2024-05-13 — tap for who they are Same subject: Even the most advanced AI cannot be followed blindly in investing, where value added is zero-sum and what is widely known is therefore worth little. — tap to centre the map on it Even the most advanced AIcannot be followed blindly ininvesting, where value addedis zero-sum and what is widely… RD Ray Dalio — holds since 2026-06-10 — tap for who they are Same subject: AI cannot get a product to the quality bar on its own, because it still works in the realm of averages. — tap to centre the map on it AI cannot get a product to thequality bar on its own,because it still works in therealm of averages. DF Dylan Field — holds since 2025-10-16 — tap for who they are Same subject: Most of the value an AI expert brings to a company is telling it not to use AI. — tap to centre the map on it Most of the value an AI expertbrings to a company is tellingit not to use AI. AK Andrej Karpathy — holds since 2025-10-17 — tap for who they are Same subject: We have neither the data nor the insight to use machine learning to pick drug targets that succeed in the clinic more often. — tap to centre the map on it We have neither the data northe insight to use machinelearning to pick drug targetsthat succeed in the clinic… DL Derek Lowe — holds since 2023-05-25 — tap for who they are Same subject: Not every bottleneck on medical progress is one AI can remove, and which ones will remain can be guessed at now. — tap to centre the map on it Not every bottleneck onmedical progress is one AI canremove, and which ones willremain can be guessed at now. JT Jacob Trefethen — holds since 2025-08-02 — tap for who they are Same subject: An AI as good as a top researcher will not be priced like one, because it competes against the other labs rather than against humans. — tap to centre the map on it An AI as good as a topresearcher will not be pricedlike one, because it competesagainst the other labs rather… CH Casey Handmer — holds since 2025-08-15 — tap for who they are Same subject: Systematising principled decision-making with AI is now the line between staying competitive and not; there is no position in between. — tap to centre the map on it Systematising principleddecision-making with AI is nowthe line between stayingcompetitive and not; there is… RD Ray Dalio — holds since 2026-06-10 — tap for who they are
same subject or similar wording

At the centre There are few clear-cut cases in biopharma today where buying an AI system is obviously worth it. Holds Derek Lowe Read this korrent →